Matthew Vander Heiden

Matthew Vander Heiden

Associate Professor of Biology; Associate Director, Koch Institute for Integrative Cancer Research

Matthew Vander Heiden is interested in the role that cell metabolism plays in mammalian physiology, with a focus on cancer.

617-715-4471

Phone

76-561

Office

mvh@mit.edu

Email

Lab Website
Peter Jansen

Assistant

617-252-1163

Assistant Phone

Education

  • PhD, 2000, University of Chicago; MD, 2002, University of Chicago
  • SB, 1994, Biological Chemistry, University of Chicago

Research Summary

We study the biochemical pathways cells use and how they are regulated to meet the metabolic requirements of cells in different physiological situations. We focus on the role of metabolism in cancer, particularly how metabolic pathways support cell proliferation. We aim to translate our understanding of cancer cell metabolism into novel cancer therapies.

Awards

  • Howard Hughes Medical Institute Faculty Scholar, 2016
  • SU2C Innovative Research Grant Recipient, 2016

Recent Publications

  1. Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Luengo, A, Li, Z, Gui, DY, Sullivan, LB, Zagorulya, M, Do, BT, Ferreira, R, Naamati, A, Ali, A, Lewis, CA et al.. 2020. Mol Cell , .
    doi: 10.1016/j.molcel.2020.12.012PMID:33382985
  2. Transcriptional activation of macropinocytosis by the Hippo pathway following nutrient limitation. Sivanand, S, Vander Heiden, MG. 2020. Genes Dev 34, 1253-1255.
    doi: 10.1101/gad.343632.120PMID:33004484
  3. Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. Lau, AN, Li, Z, Danai, LV, Westermark, AM, Darnell, AM, Ferreira, R, Gocheva, V, Sivanand, S, Lien, EC, Sapp, KM et al.. 2020. Elife 9, .
    doi: 10.7554/eLife.56782PMID:32648540
  4. Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer. Sivanand, S, Vander Heiden, MG. 2020. Cancer Cell 37, 147-156.
    doi: 10.1016/j.ccell.2019.12.011PMID:32049045
  5. Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer. Luengo, A, Abbott, KL, Davidson, SM, Hosios, AM, Faubert, B, Chan, SH, Freinkman, E, Zacharias, LG, Mathews, TP, Clish, CB et al.. 2019. Nat Commun 10, 5604.
    doi: 10.1038/s41467-019-13419-4PMID:31811141
  6. Cancer-associated mutations in human pyruvate kinase M2 impair enzyme activity. Liu, VM, Howell, AJ, Hosios, AM, Li, Z, Israelsen, WJ, Vander Heiden, MG. 2020. FEBS Lett 594, 646-664.
    doi: 10.1002/1873-3468.13648PMID:31642061
  7. Cellular redox state constrains serine synthesis and nucleotide production to impact cell proliferation. Diehl, FF, Lewis, CA, Fiske, BP, Vander Heiden, MG. 2019. Nat Metab 1, 861-867.
    doi: 10.1038/s42255-019-0108-xPMID:31598584
  8. A framework for examining how diet impacts tumour metabolism. Lien, EC, Vander Heiden, MG. 2019. Nat Rev Cancer 19, 651-661.
    doi: 10.1038/s41568-019-0198-5PMID:31530936
  9. Increased PHGDH expression promotes aberrant melanin accumulation. Mattaini, KR, Sullivan, MR, Lau, AN, Fiske, BP, Bronson, RT, Vander Heiden, MG. 2019. BMC Cancer 19, 723.
    doi: 10.1186/s12885-019-5933-5PMID:31331318
  10. Determinants of nutrient limitation in cancer. Sullivan, MR, Vander Heiden, MG. 2019. Crit Rev Biochem Mol Biol 54, 193-207.
    doi: 10.1080/10409238.2019.1611733PMID:31162937
More Publications

Multimedia